Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Account Payables

Amounts the company owes suppliers for goods and services received.

Invivyd, Inc.NASDAQ: IVVD

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 76.9% from a year ago

Account payables stood at $2.02M at the end of Q1 FY2026, down 76.9% from a year earlier and down 85.3% from the prior quarter. Over 3 fiscal years it compounded at +108.5% a year.

Context

  • Account payables amounted to 0.8% of total assets at the end of Q1 FY2026, down 7.6 pp from a year earlier.
  • Account payables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -76.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.02M-85.3% QoQ
Last fiscal yearDec 2025
$13.74M+31.5% YoY
Year agoMar 2025
$8.74M-76.9% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.9%——
1 year+31.5%——
3-year CAGR+108.5%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
13.74M USD
Year-over-year change
+31.5%
4-year CAGR
+24.2%

Account Payables vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's Mar 2026 account payables of $2.02M is the 7th highest of the 10 companies compared; the peer median is $2.13M.
  • Its year-over-year change of -76.9% is the lowest of 10, against a peer median of -9.4%.
  • Account payables amounts to 0.8% of total assets for IVVD, versus a peer median of 2.1%.
IVVD Competitors Peer median
Account Payables for IVVD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SGMOSangamo Therapeutics, Inc.Mar 2026$19.31M +6.1%-13.6%32.2%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$6.31M +13.5%+15.4%6.3%
TARAProtara Therapeutics, Inc.Mar 2026$4.03M +74.5%+29.8%2.1%
NTHINeonc Technologies Holdings, Inc.Mar 2026$2.63M -36.4%—79.1%
CDXSCodexis, Inc.Mar 2026$2.13M -64.8%-21.8%1.6%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$2.09M -9.4%-4.2%1.5%
IVVDInvivyd, Inc.Mar 2026$2.02M -76.9%+108.5%0.8%
OABIOmniAb, Inc.Mar 2026$1.65M -14.5%-14.2%0.6%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$1.62M -29.1%+26.6%4.0%
CCCCC4 Therapeutics, Inc.Mar 2026$773K +13.2%-9.9%0.2%
Peer median (excluding IVVD) $2.13M-9.4%-7.1%2.1%

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents542.22M92.08M200.64M69.35M226.69M
Short-term Investments49.19M279.92M000
Net Receivables229K377K933K11.17M14.6M
Inventory000025.5M
Other Current Assets0000(23.78M)
Total Current Assets616.71M376.92M224.88M100.68M247.47M
Property, Plant & Equipment (Net)83K6.06M4.13M2.89M3.81M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets3.3M191K175K25.94M25.61M
Total Non-current Assets3.38M6.25M4.3M28.83M29.42M
Total Assets620.09M383.17M229.18M129.52M276.88M
Account Payables5.78M1.52M7.95M10.45M13.74M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.95M6.03M10.79M3.94M5.8M
Total Current Liabilities62.06M25.03M50.29M61.98M34.16M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities12K1K700K00
Total Non-current Liabilities12K2.17M1.42M(1)1.18M
Total Liabilities62.07M27.2M51.71M61.98M35.34M
Common Stock11K11K11K12K28K
Retained Earnings(292.11M)(533.43M)(732.07M)(901.99M)(954.48M)
Accumulated OCI(8K)(272K)(13K)(5K)(41K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity558.02M355.97M177.47M67.54M241.54M
Total Debt03.72M2.17M1.3M2.49M
Net Debt(542.22M)(88.35M)(198.48M)(68.05M)(224.2M)

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.